IPC - Module 4 Flashcards

1
Q

Examples of Diseases that can be transmitted via blood

A

1) Hepatitis B (HBV)

2) Hepatitis C (HCV)

3) HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

If you are not wearing gloves, the approximate risk of infection following a poke (needle stick) with a needle contaminated with blood from an infectious patient is:

A

HIV – 0.3%
HCV – 3.0%
HBV – up to 30.0% for non-immune health care worker

If you are wearing gloves, your risk in reduced by 50% (i.e. It would be for HIV 0.15%, HCV 1.5%, HBV 15.0%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Antigen =

A

Antigen = virus = bad news (infectious)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antibody =

A

Antibody = immunity = good news

Exception: For HIV, the presence of antibody does not mean “good news”, as although antibodies are developed, the virus will not be destroyed because it is hiding inside cells of the cellular immune system. Ultimately, the cells will be destroyed, the immune system compromised, and death will result.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The word hepatitis means…

A

The word hepatitis means liver inflammation.

Hepatitis is commonly caused by viral infection of the liver but may also be caused by alcohol, bacteria, parasites, drugs, chemical toxins and other agents. The main concern for health care workers are the types of hepatitis that can be spread by blood, or other body fluids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Signs & Symptoms of Liver Problems

A

Signs and symptoms of liver problems result because the infected liver is not able to process the breakdown products of erythrocytes in a normal fashion (red blood cells). This causes bilirubin levels to build up in the blood. When levels are elevated, the bilirubin is deposited in the sclera of the eye, in the skin and even in the brain and other parts of the body. This results in yellow pigmentation known as jaundice. Excess bilirubin spills over into the urine too, giving it a dark amber (strong tea) color. Stool (feces) then appears pale because the bilirubin isn’t being processed by the liver and does not pass via the digestive tract where it normally results in a brown color.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hepatitis A & E - transmitted via

A

Strains A and E are transmitted via contaminated food and water. Consider you “AtE” them.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hepatitis B, C & D - transmitted via

A

Strains B, C and D are primarily associated with blood and other body fluids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hepatitis A (HAV) Virus

A

Hepatitis A virus (HAV) is a small virus without an envelope. People are usually infected through ingestion of water or food contaminated with feces (i.e., the “fecal–oral route”).The disease is closely associated with poor sanitation, poor personal hygiene, and oral-anal sex. The virus is thought to initially replicate in the epithelial lining of the oral cavity and the intestine before entering the circulatory system. Once in the blood stream, the virus invades the liver and replicates in the liver cells. Bile leaving the liver will carry more HAV to the intestine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Process of replication of HAV

A

The portal of entry is the oral cavity; the site of replication is the liver and the mode of exit is via bile that is a component of stool (feces)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The incubation period for hepatitis A…

A

Ranges from about 15 to 50 days

Symptoms of hepatitis A are usually not evident until two weeks after the virus has invaded the liver. Up until this time the patient may have some vague symptoms such as lethargy, loss of appetite and abdominal discomfort.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diagnoses of HAV

A

A blood sample checking for elevated levels of liver enzymes aids in diagnosing hepatitis, however, a number of agents causing inflammation of the liver will give similar results. The specific diagnosis of hepatitis A is established only by testing for antibodies against hepatitis A virus (Anti-HAV). When testing for the presence of antibodies, IgM are indicative of a recent or current infection. The confirmatory test for active infection with Hepatitis A is known as Anti-HAV IgM. Antibodies of the IgG type may be present from a past infection of Hepatitis A (Anti- HAV IgG).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Hepatitis A vaccine, though not a component of the routine immunization schedule, is recommended for:

A

Travelers to areas of poor sanitation (pre–exposure prophylaxis)
Identified contacts of people with hepatitis A (post–exposure prophylaxis) – the person makes their own antibodies. Recall that antibodies are made within 5 to 7 days following immunization, so protective levels would be present once the virus started reproducing during the 15 to 50 day incubation period.

The vaccine appears to be about 80% effective when administered within one week of exposure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hepatitis B Virus - description of virion

A

HBV is a small enveloped virus that is unusually stable for an enveloped virus. It can resist freezing, moderate heat and some chemical disinfectants.

The complete virion consists of a nucleic acid core surrounded by a protein coat. Surrounding this is an envelope with spikes.

There are three antigenic areas associated with the viral particle:

Hepatitis B surface antigen (HBsAg) is part of the outer envelope.
Core antigen (HBcAg)
E antigen (HBeAg)
The core antigen and “e” antigen are part of the protein coat surrounding the nucleic acid.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HBV - Viral Replication in the Host

A

The most efficient way for HBV to enter a human host is by direct entry into the blood stream. The virus may also enter through mucous membranes. Oral mucosa, genital mucosa and the conjunctiva of the eye are all known portals of entry for HBV. Once the virus has entered the host, it is transported by the circulatory system to the liver, where the virus replicates in liver cells. Viral replication tends to be slow, contributing to a long incubation period.

While HBV is actively replicating in the liver, the virus is carried in the blood to other body fluids. Blood, saliva, spinal fluid, tears, urine, semen, vaginal secretions and mother’s milk have all been found to contain HBV during this active stage of the infection.

Animals do not serve as a reservoir for HBV and man is the only known host for this virus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Types of Symptoms/Infections for HBV

A
  1. Asymptomatic Infections
    Most people infected with HBV (60–70%) will have no disease symptoms and will never be aware of the viral infection unless tested for hepatitis B antigens.
  2. Symptomatic Infections - symptoms occur 2-6 weeks after exposure. Viral replication causes inflammation of the liver, malaise, anorexia, nausea, vomiting and abdominal discomfort. Some patients experience joint pain. This is caused by antigen–antibody complexes attaching to joint membranes which results in inflammation. jaundice similar to that seen in other liver infections. Extreme itching of the skin is common due to accumulation of bilirubin (a breakdown product of old red blood cells normally disposed of by the liver) in skin tissue.
  3. Fulminant Infections - rapid, sudden sever form seen in 1-3% of infected individuals. Usually young people with good immune system affected. Viral infected cells of the liver are recognized by T cells of the cellular immune system as being foreign or damaged. The response of the T cell is to destroy these viral laden cells. If the majority of liver cells are infected, this cell destruction will cause complete liver failure. The patient will enters a hepatic coma and severe cases may cause death unless a liver transplant can be done.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

HBV Carriers

A

Between 5 and 10% of people infected with the hepatitis B virus, even if asymptomatic, will become carriers.

  1. Carriers are a reservoir of HBV and certain bodily fluids are infectious for several years.
  2. Chronic viral infection of liver cells predisposes individuals to primary hepatocellular carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Transmission of HBV

A

Most cases of hepatitis B are transmitted through infected blood. The amount of virus needed to transmit hepatitis B is very small. Minute amounts of blood may infect a person. The virus has been found to be infective in blood spills for periods up to one week at room temperature making blood–stained clothing and bandages hazardous to handle.

Other body fluids that may transmit: Saliva, semen, spinal fluid, vag secretions, breast milk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

he following body substances are NOT implicated in the transmission of HBV unless visibly contaminated with blood:

A

feces
nasal secretions
sputum
sweat
tears
urine
vomitus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Summary of laboratory test results for HBV

A

HBsAg - Hepatitis B surface antigen - Found on outer envelope of the virus - Diagnostic test for hepatitis B infection

anti HBs - Hepatitis B surface antibodies - Produced by the patient in response to the surface antigen - Indicates one of: Patient is recovering from HBV or has been immunized

21
Q

Summary of Supplementary Serological tests used in diagnosis, prognosis and treatment of HBV

A

Anti HBc - Hepatitis B
core antibodies - Produced by the patient in response to core antigen - Diagnostic test for HBV during convalescent window

HBeAg - Hepatitis B “e” antigen - Hepatitis B
“e” antigen - Indicates all body fluids are infectious

Anti HBe - Anti HBe - Produced by the patient in response to “e” antigen - Indicates patient is clearing “e” antigen and becoming less infective

22
Q

Preventive Measures for HBV

A

Routine Practices
Routine Practices have been adopted to eliminate the risk of transmission of HBV from patients to health care workers. Patients do not arrive at a health care facility with HBV stamped on their forehead and there is no way of knowing if the patient is infective. Routine practices assume all patients to be infectious and the same precautions are applied universally. The procedures dictate the use of gloves, goggles and protective clothing when handling blood and other body fluids.

Hepatitis B Immunization
Many health care organizations require immunization of their employees against hepatitis B. The hepatitis B vaccine is given in a series of three shots and a protective level of antibodies may not be present until after the third shot. Testing is ongoing to determine when booster shots will be required. Routine practices are still applied when handling body fluids, as some individuals may not have a protective level of antibodies from immunization yet.

Hepatitis B Immune Globulin
A product called hepatitis B immune globulin (HBIG) is available for short–term prevention when a health care worker has been exposed to infectious material. This should be administered within 48 hours of exposure.

23
Q

Percentage of Hepatitis cases that are HCV

A

Hepatitis C accounts for approximately 20% of all cases of acute hepatitis. Most cases of hepatitis C are now associated with intravenous drug abuse.

24
Q

Infection & Carriers of HCV

A

Most of those infected are asymptomatic, or have possible vague, flu–like symptoms
More than half of those infected become chronic carriers
Approximately a quarter of chronic carriers will develop cirrhosis in 20 years with increased risk of hepatic cancer
Many chronic carriers suffer from chronic or intermittent fatigue
Current treatment options include antiviral medication, often in pill form and taken once/day. Old standard treatments such as ribavirin with or without interferon are still less commonly prescribed but can be used along with newer medications that are chosen based on first-line, second-line options for individual patient need. Names such as Elbasvir, Gaszoprevir, Glecaprevir, Pibrentasvir may identify a patient being treated for Hepatitis C.

25
Q

Hepatitis D (Delta Agent)

A

Hepatitis D virus (HDV) is a defective RNA virus that can only replicate in the presence of hepatitis B virus. Chronic infection with HBV along with HDV is often associated with progressive liver damage and fulminant hepatitis. About 30% of fulminant hepatitis infections are due to coinfection of HBV and HDV.

Hepatitis D virus is known to be spread in blood, semen and vaginal secretions. About 15 million people in the world are infected with HDV with the infection being endemic in parts of Africa, the Middle East, Italy and the Amazon basin. Outbreaks in North America and Europe have been associated with illicit drug use.

The best protection against HDV is immunization against hepatitis B. HDV is unable to infect liver cells without the presence of hepatitis B virus.

26
Q

Hepatitis E

A

Hepatitis E is spread by the fecal–oral–route, similar to hepatitis A.

However, the mortality rate is higher than for HAV and infections are especially serious for pregnant females with a 20% mortality rate reported. Hepatitis E infections are most common in developing countries due to poor sanitation and limited access to clean water.

27
Q

Hepatitis A Summary

A

Causative Agent - Naked virus

What the Virus Causes - Patient usually symptomatic.
If Symptoms: Jaundice, dark urine, pale stool, malaise (fatigue), loss of appetite, abdominal pain, nausea, vomiting

Carriers - No
Chronic Liver Damage - No

Transmission - Transmitted by fecal–oral route usually through ingestion of contaminated food or water

Mother to Baby - No
Sex transmitted - No
Vaccine - Yes

Immune Globulin - Yes – gamma globulin or hepatitis A immune globulin

Diagnosis - Anti–HAV

28
Q

HBV Summary

A

Causative Agent - Enveloped virus

What the Virus Causes - About 50% asymptomatic Inflammation of the liver.
If Symptoms: Jaundice, dark urine, pale stool, malaise (fatigue), loss of appetite, abdominal pain, nausea, vomiting.

Carriers - Yes (5–10%)
Chronic Liver Damage - Can be

Transmission - Contact with contaminated blood, blood products, saliva, CSF, semen, vaginal secretions, breast milk, mucous membrane or broken skin

Mother to Baby - Yes
Sex transmitted - Yes
Vaccine - Yes
Immune Globulin - Yes – HBIG

Diagnosis - HBsAg

29
Q

HCV Summary

A

Causative Agent - Enveloped virus

What virus causes - Most (80%) asymptomatic
If Symptoms: Jaundice, dark urine, pale stool, malaise (fatigue), loss of appetite, abdominal pain, nausea, vomiting

Carriers - Yes (60–90%)
Chronic Liver Damage - Can be

Transmission - Contact with contaminated blood, blood products or broken skin

Mother to Baby - Uncommon
Sex transmitted - Very poorly
Vaccine - No
Immune Globulin - No
Diagnosis - NAT for viral nucleic acid (Ag)
Anti–HCV

30
Q

The term HIV is used to describe..

A

The term HIV is used to describe infection with the virus. The patient will be generally asymptomatic and unaware that they are infected.

31
Q

The term AIDS is used when..

A

The term AIDS is used when clinical symptoms of opportunistic infections become evident.

32
Q

HIV is an enveloped RNA “retrovirus” with glycoprotein spikes. Components include:

A

The Core - the center of virus, has 2 strands of RNA, has reverse transcriptase enzyme used to produce viral DNA from its RNA (Retrovirus)

The Protein Coat - surrounds the core, consists of several proteins, one of which is designated p24 (protein 24)

The Lipid Envelope - has a lipid bilayer from which large glycoprotein spikes protrude like lolipops. The candy part of the lolipop is a glycoprotein called gp120. It is responsible for binding the virus to the host cell

33
Q

Viral Hardiness of HIV

A

HIV is not very hardy. There is evidence of viral survival outside the human host for about a week. The amount of virus surviving outside the host appears to be below the infective dose necessary to transmit infection. Culture of HIV is more difficult than for most other viruses and is not routinely done. This makes it difficult to accurately evaluate the true viability of the virus.

34
Q

Cleaning methods for HIV virus

A

It is generally accepted that routine sterilization, disinfection and cleaning methods used in the health care setting do not need to be altered for HIV contamination. Most disinfectants with antiviral properties are effective and washing laundry in hot water and detergent will inactivate the virus.

35
Q

How does viral replication take place?

A
  1. Binding - to a susceptible host cell. The glycoprotein will bind only to host cells that have a membrane receptor for gp 120. T-helper lymphocytes (CD4 cells) of the cellar immune system have this receptor.
  2. Penetration - of the virus and shedding of the protein coat
  3. Reverse transcription - (viral RNA is used as a template to produce viral DNA) and incorporation of the viral DNA into a chromosome of the host cell
  4. Dormant period - Once incorporated in the host cell’s chromosome, the viral DNA may remain dormant for a variable period of time. The person is infected with HIV but has no symptoms (no disease).
  5. Viral replication - The host cell is somehow activated and viral parts are synthesized. Component parts are assembled at the host cell membrane, forming like a bud. The new virus is ready to infect another CD4 cell.
36
Q

Effect of HIV on Host Cells

A

The HIV virus may remain latent in the host cells for long periods, but once the virus is activated to replicate, the virus kills the CD4 cells.

It is the loss of CD4 cells that brings on clinical symptoms of AIDS. The CD4 cells are part of the cellular immune system and are the helper cells that turn on both the cellular and humoral parts of the immune system.

Imbalance of CD4 & CD8 Cells (suppressor cells) result is a dysfunctional immune system, which makes the host susceptible to all kinds of low grade or opportunistic pathogens that normally do not cause disease.

37
Q

Diagnostic Tests for HIV

A

Testing for HIV antigen is not routinely performed as there is very little virus (antigen) in the blood. The virus rapidly enters cells once it enters the body. The initial routine test for HIV is a screen test for antibodies to one of the component parts of the virus (e.g., anti-gp120) as the antibodies are readily found in the blood.

Most individuals show detectable levels of HIV antibodies within 4-12 weeks of exposure. However, there are cases where people have not developed antibodies until several months or years after infection.

38
Q

What is the Negative Window for HIV?

A

The negative window is the period of time when the person is infected, but detectable levels of antibodies are not yet present. Therefore, a negative screen test does not rule out infection.

39
Q

Western Blot Assay

A

The Western Blot Assay is currently used as the confirmatory test for HIV. This test will identify several specific HIV antibodies directed against specific viral proteins such as gp120, gp 160 (another glycoprotein component) and p24. The Western Blot is expensive and takes longer to run than the initial screen. False positives can still occur with this test but the incidence is quite low.

The negative window problem is not solved with this test since it is, like the screen test, detecting antibodies.

40
Q

Infection of HIV

A
  1. Primary Infection - period 2-6 weeks after contact, patient may be asymptomatic or have vague flu-like symptoms, antibodies to HIV may not be present, symptoms (if present) subside spontaneously without treatment - enters latent period
  2. Latent Period - generally asymptomatic, HIV slowly destroys CD4 cells, antibodies to HIV appear during this period (positive blood test), lasts for 2-5 years (but may be longer), no symptoms but infectious
  3. Clinical Aids - virus becomes active, CD4 count drops to below 200 (600 is normal), opportunistic infections present (pneumonia, shingles, oral thrush), may develop various other viral, bacterial or fungal infections, cancers, such as Kaposi’s sarcoma, and lymphomas, Without specific therapy, most patients die within two to five years after the onset of clinical AIDS
41
Q

Infections associated with a Clinical diagnosis of AIDS

A

Cancer (Kaposi’s Sarcoma)
Protozoa (Pneumocystis pneumonia)
Fungi (Candida yeast infection)
Fungi (Severe Candida yeast infection)
Virus ( Herpes re-activation)

42
Q

Treatment of HIV Positive Patients

A

There is no cure for AIDS. Extensive research is ongoing in an effort to find an antiviral drug or combination of drugs, or a vaccine.

43
Q

ZDV (zidovudine) also called AZT

A

was the first drug used in the management of HIV patients in 1987 and is still in use. The drug slows viral replication in host cells and prolongs the latent period. In the mid 1990s, it was felt that the development of new drugs could possibly eradicate the virus from the patient’s system, however, this research is still ongoing.

44
Q

Transmission for HIV

A

Known routes of infection include the following:

Anal and vaginal intercourse
Needle sharing among intravenous drug users
Mother to fetus; mother to baby at birth; mother to baby in breast milk
Needle stick accidents
Blood contamination on broken skin
Blood splashes to mucous membranes
Shared tattoo needles
Transfusion with contaminated blood and blood products (prior to screening programs)

45
Q

On the job risks of being infected with HIV have been identified as follows:

A

Accidental Needle Stick

Blood Splashes

Blood Contact

46
Q

The following would be considered significant exposure to blood:

A

Patient blood contacting the broken (non intact) skin of a health care worker
Patient blood contacting the mucous membrane of a health care worker

47
Q

What to do Following a significant blood exposure:

A

-Patient blood contacting the broken skin of a health care worker
-Patient blood contacting the mucous membrane of a health care worker

  1. Treat Exposure Site
    -Allow bleeding to occur
    -Wash thoroughly with soap and water
    -Wash mucous membrane or eye thoroughly with water
  2. Notification
    -Report incident to appropriate authority
    -Fill out incident report
  3. Blood Test on Health Care Worker
    -Test for hepatitis B, hepatitis C and HIV
    -Blood Test on Patient
    -Request hepatitis B, hepatitis C and HIV status
  4. Treatment
    -Confer with occupational health regarding the need of ZDV or HBIG
  5. Follow up
    -Blood tests for HIV antibodies when recommended by occupational health
48
Q

SARS Severe Acute Respiratory Syndrome

A

SARS is spread through close contact with an infected person. Examples include living in the same household, providing care to someone with SARS or having direct contact with respiratory secretions and body fluids of someone affected by SARS.

Symptoms of SARS include fever, chills, shortness of breath, fatigue, headaches and in some, loss of smell or taste

49
Q

Procedure for Health Care Worker regarding Covid/SARS

A

Health care workers (HCW) should maintain a distance of 2 meters while questioning patient. (1 meter was recommended prior to 2009)

Screening Questions:

Do you have new or worsening cough or shortness of breath?
Do you have chills or fever?
If yes to either question, the HCW should don an N95 respirator or equivalent, plus eye protection. Persons accompanying the patient should don a surgical mask. Patient should don a surgical mask and perform hand hygiene. Lastly, move the patient to an area separate from others.

Hand hygiene, gloves, N95 respirators, eye protection and gowns are required for health care workers.

Hair and shoe covers are not recommended. World Health recommends foot wear that can be decontaminated.

Negative pressure room is not currently recommended.

Transport of patients: Recommend HCW wear N95 respirator, eye protection, gown, gloves. Remove immediately upon completion of transport.

Patients should be out of their rooms for essential procedures only and should wear a surgical mask during transport.

Notify area that patient is being transported to.